Home > Riviste > Minerva Ortopedica e Traumatologica > Fascicoli precedenti > Minerva Ortopedica e Traumatologica 2018 March;69(1) > Minerva Ortopedica e Traumatologica 2018 March;69(1):12-5

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo

 

ORIGINAL ARTICLE   

Minerva Ortopedica e Traumatologica 2018 March;69(1):12-5

DOI: 10.23736/S0394-3410.17.03844-9

Copyright © 2017 EDIZIONI MINERVA MEDICA

lingua: Inglese

Study on the clinical efficacy of therapy in mild to moderate degree knee arthrosis only through oral chondroprotection

Emy BRUNELLO

Private Practitioner, Verona, Italy


PDF


BACKGROUND: Oral administration of molecules that can positively influence the clinical course of osteoarthritis (OA) and joint tissue metabolism (chondroprotection) is used in clinical practice either as a monotherapy or as a combination of several substances.
METHODS: In this study it was investigated whether the combined oral chondroprotection with Syalox® Plus 300 mg (based on high molecular weight hyaluronic acid obtained by means of biofermentatation technology and Boswellia Serrata containing acid 3-0-acetyl-11-keto-β-Boswellic that is useful for joint function).
RESULTS: After the improvement at 3 and at 5 weeks and at 7 weeks the group of patients still maintained the improvement without any adverse effects, and the recourse to NSAIDs diminished.
CONCLUSIONS: The treatment may be useful in relieving symptoms and preserving the state of articular wellbeing in mild to moderate knee OA.


KEY WORDS: Boswellia - Chondroitin - Osteoarthritis, knee

inizio pagina